Stanley Lapidus - Sep 25, 2023 Form 4 Insider Report for Lucid Diagnostics Inc. (LUCD)

Role
Director
Signature
/s/ Michael A. Gordon, by power of attorney
Stock symbol
LUCD
Transactions as of
Sep 25, 2023
Transactions value $
-$43,459
Form type
4
Date filed
9/27/2023, 08:53 PM
Previous filing
Sep 27, 2023
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUCD Common stock Sale -$286 -200 -0.15% $1.43 131K Sep 25, 2023 Direct F1, F2, F3
transaction LUCD Common stock Sale -$14.7K -10K -7.61% $1.47 121K Sep 26, 2023 Direct F1, F2, F3
transaction LUCD Common stock Sale -$14.3K -10K -8.24% $1.43 111K Sep 26, 2023 Direct F1, F2, F3
transaction LUCD Common stock Sale -$14.1K -9.75K -8.75% $1.45 102K Sep 26, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.
F2 Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.
F3 The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.